151 related articles for article (PubMed ID: 32546046)
1. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
4. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
5. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
7. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Serum Integrin αvβ3 & Vitronectin in the Early Diagnosis of Breast Cancer.
Radwan AF; Ismael OE; Fawzy A; El-Mesallamy HO
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307158
[TBL] [Abstract][Full Text] [Related]
9. Development of a gas chromatography-mass spectrometry method for breast cancer diagnosis based on nucleoside metabolomes 1-methyl adenosine, 1-methylguanosine and 8-hydroxy-2'-deoxyguanosine.
Omran MM; Rashed RE; Darwish H; Belal AA; Mohamed FZ
Biomed Chromatogr; 2020 Jan; 34(1):e4713. PubMed ID: 31633807
[TBL] [Abstract][Full Text] [Related]
10. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Zajkowska M; Gacuta E; Kozłowska S; Lubowicka E; Głażewska EK; Chrostek L; Szmitkowski M; Pawłowski P; Zbucka-Krętowska M; Ławicki S
Adv Med Sci; 2019 Mar; 64(1):1-8. PubMed ID: 30227310
[TBL] [Abstract][Full Text] [Related]
12. Study on Urinary Candidate Metabolome for the Early Detection of Breast Cancer.
Zahran F; Rashed R; Omran M; Darwish H; Belal A
Indian J Clin Biochem; 2021 Jul; 36(3):319-329. PubMed ID: 34220007
[TBL] [Abstract][Full Text] [Related]
13. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
15. Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer.
Cui R; Wang C; Zhao Q; Wang Y; Li Y
Anticancer Agents Med Chem; 2020; 20(17):2053-2065. PubMed ID: 32619179
[TBL] [Abstract][Full Text] [Related]
16. Analysis of blood markers for early breast cancer diagnosis.
Bayo J; Castaño MA; Rivera F; Navarro F
Clin Transl Oncol; 2018 Apr; 20(4):467-475. PubMed ID: 28808872
[TBL] [Abstract][Full Text] [Related]
17. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
[TBL] [Abstract][Full Text] [Related]
18. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
20. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]